Monash IVF Group Limited (MVF.AX)

Monash IVF Group Limited (MVF.AX) — VMCI valuation read

Monash IVF Group Limited (MVF.AX) carries a VMCI composite of 57/100, 7 points above the Healthcare sector median of 50. Among mid-cap names, that gap places MVF.AX in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The MVF.AX insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads MVF.AX trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.5x leaves covenant headroom, the line to track on Monash IVF Group Limited's next 10-Q.

MVF.AX rose 2.0% over the trailing 7 days, with a -18.9% read on a 30-day basis.